SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
Positive results show Pentarlandir is safe and effective in patients with mild-to-moderate COVID-19 LOS ANGELES & NEW TAIPEI CITY, Taiwan–(BUSINESS WIRE)–SyneuRx™ International (TPEX:6575), a global biotech company focused on the development of new classes of drugs for COVID-19 and multiple major central nervous system disorders, today announced results from its phase 2 clinical trial evaluating … [Read more…]
